In particular, combinations of ALK inhibitors with PD-1/PD-L1 therapies have shown early promises in advanced ALK-positive NSCLC, but yet drawing attention to the right drug combinations with good safety profiles. This evidence concerns the gene ALK and non-small cell lung carcinoma.